enGene Reports Updated LEGEND Data, But No Clear Differentiation Yet

What happened

enGene announced additional interim results from the pivotal cohort of its Phase 2 LEGEND trial of detalimogene in BCG-unresponsive NMIBC with CIS. The update likely reinforces prior efficacy signals (71% any-time CR, 47% 6-month CR) but does not yet demonstrate superiority over established competitors like Adstiladrin and Anktiva. With a market cap around $570M and cash runway into 2H28, the stock already prices in a meaningful probability of approval. The lack of a clear efficacy or durability edge keeps the risk-reward balanced, and the wait-and-see stance remains appropriate until full pivotal data and regulatory feedback emerge.

Implication

Investors should maintain patience: the key catalyst is still the complete pivotal dataset and BLA submission in 2H26. Until then, enGene remains a speculative binary story with a crowded competitive landscape, and the current price offers no margin of safety.

Thesis delta

No material shift. The updated interim results are consistent with prior disclosures and do not alter the competitive dynamics or probability-weighted value. The thesis remains on hold pending more definitive evidence of differentiation.